Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.
about
The NF-κB Pathway and Cancer Stem Cellsc-Rel and its many roles in cancer: an old story with new twistsNF-κB in cellular senescence and cancer treatmentBiosensors in clinical practice: focus on oncohematology.IKK/NF-κB signaling contributes to glioblastoma stem cell maintenance.Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AML.Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition.The paracaspase MALT1 cleaves HOIL1 reducing linear ubiquitination by LUBAC to dampen lymphocyte NF-κB signalling.Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-κB activation.Regulation of NF-κB by the CARD proteinsWhole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma.Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.Anti-cancer activity of withaferin A in B-cell lymphoma.NF-κB and AKT signaling prevent DNA damage in transformed pre-B cells by suppressing RAG1/2 expression and activityA roadmap of constitutive NF-κB activity in Hodgkin lymphoma: Dominant roles of p50 and p52 revealed by genome-wide analyses.Cooperative Control of Caspase Recruitment Domain-containing Protein 11 (CARD11) Signaling by an Unusual Array of Redundant Repressive Elements.Intramolecular Interactions and Regulation of Cofactor Binding by the Four Repressive Elements in the Caspase Recruitment Domain-containing Protein 11 (CARD11) Inhibitory Domain.A pathway switch directs BAFF signaling to distinct NFκB transcription factors in maturing and proliferating B cells.MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium PrMALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivoIt takes two to tango: IκBs, the multifunctional partners of NF-κB.Regulation of NF-κB by ubiquitination and degradation of the IκBs.DNA damage-dependent NF-κB activation: NEMO turns nuclear signaling inside out.Regulation of cell death and autophagy by IKK and NF-κB: critical mechanisms in immune function and cancer.NF-κB and the link between inflammation and cancer.Nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents--a comprehensive review of biology, clinical course and treatment options.Diffuse large B cell lymphoma: molecular targeted therapy.Diffuse large B-cell lymphoma-treatment approaches in the molecular era.Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.Roles of the NF-κB Pathway in B-Lymphocyte Biology.Histone acetyltransferase-deficient p300 mutants in diffuse large B cell lymphoma have altered transcriptional regulatory activities and are required for optimal cell growth.TNF receptor-associated factor 6 regulates proliferation, apoptosis, and invasion of glioma cells.Piperlongumine inhibits proliferation and survival of Burkitt lymphoma in vitro.Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.miR-28 regulates the germinal center reaction and blocks tumor growth in preclinical models of non-Hodgkin lymphoma.From Waldenström's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation.The taming of the NF-κB: PP4R1 navigates while PP4c dephosphorylates.CKIP-1 is an intrinsic negative regulator of T-cell activation through an interaction with CARMA1.A quantitative signaling screen identifies CARD11 mutations in the CARD and LATCH domains that induce Bcl10 ubiquitination and human lymphoma cell survival.Harnessing downstream NF-κB signalling to achieve apoptosis-inducing anti-cancer-specific activity.
P2860
Q26750605-F8F99973-4642-498E-A119-7259FE94E7E5Q26772234-85C64E4F-51CE-47FF-A0CD-DCCB3CA545FCQ27007045-F2A31935-75F6-42F6-8CC3-CCF2F0F31609Q27027114-8982599C-EAA6-44E1-8266-AE8CD199A310Q33276239-0E3F629E-7E93-4E3B-B9D3-B255AC0D3746Q33703030-D5061EF2-BF0A-4D1B-91BD-994EE531199CQ33824463-B4960CFC-7A11-4128-80BB-AE216D3047D3Q34500164-87BEF61F-2FE3-4BF4-9CF8-D28D6AD65504Q34521887-AF400E34-21BE-4668-B6D9-8F02D4B996B1Q35920998-48091D64-FB6D-412D-A580-5CCB5A863924Q36022544-241C1380-DF9F-4800-B716-D72DE7CB6F4CQ36192439-659D2A7A-9EE8-42A6-AE1C-48D2E4B37662Q36213500-B4C51A82-A02B-4B89-A4C8-C3DDE7B395DDQ36351111-4175CFCF-7831-401D-838D-36B4227A287CQ36694809-826314FD-8B69-479F-83DF-07870B8DAEACQ36884567-8BF29E01-1D2A-4FC3-AD2F-90905A684694Q36884572-2BDA49E5-5B9E-499D-81BC-B0B8B69B7B94Q36957946-B9B04406-71E8-41E5-ABEC-6058A1C8694BQ37006876-4E9E5672-F7D9-4CEA-A5DC-606506C36DD8Q37699271-95C19F50-EA76-46C5-8CB4-CDF1679D0ADDQ37995679-0EFA35B7-6B39-4165-8F4D-890820DBBC07Q37995680-CE8C6134-BC5F-4394-B5C8-29AE387C6BB8Q37995692-F49E1D11-9DDF-40CA-8280-DCB0C280E6C3Q37995693-8AB85DF3-F09B-4036-B271-16EDB20F7F22Q37995696-38ED0A97-8B5E-4D0B-8A50-F48B6E629A4DQ38044928-48ED529A-9FAE-41AA-B938-94E9F8D147A7Q38053983-D3AE80A0-2402-4D32-9CE0-1D57FB394A96Q38161760-8A62DF39-DBB1-4F74-82A9-64E5CC22DA9CQ38311898-9832E45A-2332-4669-8460-E044AE8139BCQ38567094-2E136C2F-D679-43C2-8CA3-2E67CC2C6233Q39023825-B0B081CC-2EB0-4798-A7AF-76A97F4EDE2BQ39202910-6C4EBF85-0D8D-4307-BDE9-20AF5153EFBFQ39226853-F751911F-F92D-47CB-968B-2A22EE75DEDFQ39406673-8ABABB53-773B-45E5-9717-8D9FDD280F5FQ40340268-F3D37B86-2930-4241-B06B-7F6F5207F5ABQ41177165-041DF0E7-154C-4A6D-8460-0275DDF50C7EQ41345277-EEEE55E1-79AB-44D0-B0D8-F8DA90683F35Q41877667-C3CF9443-127B-4A5A-B9B8-8EFF2A1313DFQ41883159-CFCDA610-361C-4DB4-86C3-9BBEA1968924Q42140851-F19E75BF-F7BF-4CB6-BBFF-6BE3F15EF2A2
P2860
Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.
@ast
Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.
@en
type
label
Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.
@ast
Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.
@en
prefLabel
Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.
@ast
Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.
@en
P2093
P2860
P1476
Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.
@en
P2093
Kian-Huat Lim
Louis M Staudt
Yibin Yang
P2860
P304
P356
10.1111/J.1600-065X.2012.01105.X
P577
2012-03-01T00:00:00Z